Shares of Cancer Genetics Inc (NASDAQ:CGIX) have been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $5.00.
Several analysts have recently weighed in on CGIX shares. HC Wainwright set a $3.00 price objective on shares of Cancer Genetics and gave the company a “buy” rating in a research report on Tuesday, May 29th. Zacks Investment Research raised shares of Cancer Genetics from a “sell” rating to a “hold” rating in a report on Monday, May 14th. ValuEngine raised shares of Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Maxim Group lowered shares of Cancer Genetics from a “buy” rating to a “hold” rating and set a $6.00 target price on the stock. in a report on Tuesday, April 3rd. Finally, Dawson James lowered shares of Cancer Genetics from a “buy” rating to a “neutral” rating in a report on Friday, April 6th.
NASDAQ CGIX opened at $0.90 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.92 and a current ratio of 0.92. The firm has a market cap of $24.97 million, a PE ratio of -1.14 and a beta of 1.28. Cancer Genetics has a 52 week low of $0.82 and a 52 week high of $4.25.
Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Tuesday, May 15th. The medical research company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). The company had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $10.20 million. Cancer Genetics had a negative net margin of 52.87% and a negative return on equity of 77.26%. sell-side analysts expect that Cancer Genetics will post -0.46 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Cancer Genetics stock. Two Sigma Securities LLC boosted its position in Cancer Genetics Inc (NASDAQ:CGIX) by 363.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 67,677 shares of the medical research company’s stock after acquiring an additional 53,061 shares during the period. Two Sigma Securities LLC owned 0.24% of Cancer Genetics worth $125,000 at the end of the most recent reporting period. 16.97% of the stock is currently owned by hedge funds and other institutional investors.
About Cancer Genetics
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.